An assessment of the design and dissemination of phase I clinical trials: where can we improve?

被引：0
|
作者：
Copsey, Bethan [1 ]
Odutayo, Ayodele [2 ]
Cook, Jonathan [2 ]
Dutton, Susan [2 ]
Altman, Douglas [2 ]
Hopewell, Sally [2 ]
机构：
[1] Univ Oxford, Oxford, England
[2] Univ Oxford, Nuffield Dept Orthopaed Rheumatol & Musculoskelet, Oxford, England
来源：
TRIALS | 2017年 / 18卷
关键词：
D O I：
暂无
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
P220
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Clinical Trials Transparency: Where Are We Today?
    Dal-Re, Rafael
    TRENDS IN CANCER, 2018, 4 (01): : 1 - 3
  • [22] Globalization of Clinical Trials - Where are We Heading?
    George, Melvin
    Selvarajan, Sandhiya
    Suresh-Kumar, S.
    Dkhar, Steven A.
    Chandrasekaran, Adithan
    CURRENT CLINICAL PHARMACOLOGY, 2013, 8 (02): : 115 - 123
  • [23] Cooperative clinical trials in PV: Where are we?
    Werth, V
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2002, 118 (04) : 738 - 738
  • [24] Clinical Trials in Heart Failure: Where Are We?
    Pothineni, Naga Venkata K.
    Kattoor, Ajoe J.
    Kovelamudi, Swathi
    Kenchaiah, Satish
    CIRCULATION, 2016, 134
  • [25] Can we design and replicate clinical trials with a multiple drug focus
    O'Brien, CP
    Lynch, KG
    DRUG AND ALCOHOL DEPENDENCE, 2003, 70 (02) : 135 - 137
  • [26] Lung Cancer Screening: Where Are We, and How Can We Improve?
    Suzuki, Kei
    Ceppa, DuyKhanh P.
    THORACIC SURGERY CLINICS, 2023, 33 (04) : XIII - XIV
  • [27] The i3+3 design for phase I clinical trials
    Liu, Meizi
    Wang, Sue-Jane
    Ji, Yuan
    JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2020, 30 (02) : 294 - 304
  • [28] Can we improve the statistical analysis of vascular prevention trials? Assessment of ordinal outcomes
    Bath, Philip M.
    Geeganage, Chamila
    Gray, Laura J.
    Collier, Timothy
    Pocock, Stuart
    STROKE, 2007, 38 (02) : 523 - 524
  • [29] Can we improve patient selection for phase I clinical trials (phI1) based on immuno-oncology score prognostic index (VIO)?
    Matos Garcia, I.
    Hierro, C.
    Martin-Liberal, J.
    Viaplana, C.
    Azaro, A.
    Brana, I.
    Vieito Villar, M.
    Saavedra, O.
    Gardeazabal, I.
    Ros, J.
    Prieto, P.
    Berche, R.
    Munoz-Couselo, E.
    Oliveira, M.
    Elez Fernandez, E.
    Felip, E.
    Carles, J.
    Tabernero, J.
    Dienstmann, R.
    Garralda, E.
    ANNALS OF ONCOLOGY, 2019, 30
  • [30] Phase I design with new targets; do we need new designs for phase I trials?
    Harris, AL
    ANNALS OF ONCOLOGY, 1998, 9 : 5 - 5
12345